Sepsis after major visceral surgery is associated with sustained and interferon-γ-resistant defects of monocyte cytokine production

Surgery

Volumn 127, Issue 3, 2000, Pages 309-315

  Weighardt, Heike ^a   Heidecke, Claus Dieter ^a   Emmanuilidis, Klaus ^a   Maier, Stefan ^a   Bartels, Holger ^a   Siewert, Jörg Rüdiger ^a   Holzmann, Bernhard ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR;

ABDOMINAL SURGERY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; SEPSIS; SURVIVAL; TREATMENT OUTCOME;

EID: 0034093258     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.2000.104118     Document Type: Article

References (44)

1. 1. Medzhitov R, Janeway CA. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997;91:295-8.
2. 2. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996; 272:50-4.
3. 3. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93.
4. 4. Allen JE, Maizels RM. Th1-Th2: Reliable paradigm or dangerous dogma? Immunol Today 1997;18:387-92.
5. 5. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998; 8:275-83.
6. 6. Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998;8:383-90.
7. +T cells. J Exp Med 1997;185:461-9.
8. 8. Karpus WJ, Lukacs NW, Kennedy KJ, Smith WS, Hurst SD, Barrett TA. Differential CC chemokine-induced enhancement of T helper cell cytokine production. J Immunol 1997; 158:4129-36.
9. 9. Shibuya K, Robinson D, Zonin F, Hartley SB, Macatonia SE, Somoza C, et al. IL-1α and TNF-α are required for IL-12-induced development of Th1 cells producing high levels of IFN-γ in BALB/c but not C57BL/6 mice. J Immunol 1998; 160:1708-16.
10. 10. Lamont AG, Adorini L. IL-12: a key cytokine in immune regulation. Immunol Today 1996;17:214-7.
11. 11. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-76.
12. 12. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998;16:495-521.
13. 13. Schijns VECJ, Haagmans BL, Wierda CMH, Kruithof B, Heijnen IAFM, Alber G, et al. Mice Lacking IL-12 develop polarized Th1 cells during viral infection. J Immunol 1998; 160:3958-64.
14. 14. Fisher CJ, Dhainaut J-FA, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-43.
15. 15. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991;324:429-37.
16. 16. Abraham E, Anzueto A, Gutierrez G, Tessler S, Pedro GS, Wunderink R, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998;351;929-33.
17. 17. Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991;266:1097-102.
18. 18. Fisher CJ, Agost JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein: the soluble TNF receptor sepsis study group. N Engl J Med 1996;334:1697-702.
19. 19. Abraham E, Raffin TA. Sepsis therapy trials: Continued disappointment or reason for hope? JAMA 1994;271:1876-8.
20. 20. Bone RC. Why sepsis trials fail. JAMA 1996;276:565-6.
21. 21. Sprung CL, Finch RG, Thijs LG, Glauser MP. International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. Crit Care Med 1996;24:1441-7.
22. 22. Warren HS. Strategies for the treatment of sepsis. N Engl J Med 1997;336:952-3.
23. 23. Eidelman LA, Pizov R, Sprung CL. New therapeutic approaches in sepsis: a critical review. Intensive Care Med 1995;21:269-72.
24. 24. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-55.
25. 25. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996;24:1125-8.
26. 26. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112:235-43.
27. 27. Munoz C, Cadet J, Fitting C, Misset B, Blériot J-P, Cavaillon J-M. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991;88:1747-54.
28. 28. Ertel W, Keel M, Neidhardt R, Steckholzer U, Kremer JP, Ungethuem U, et al. Inhibition of the defense system stimulating interleukin-12 interferon-γ pathway during critical illness. Blood 1997;89:1612-20.
29. 29. Sheppard BC, Fraker DL, Norton JA. Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. Surgery 1989;106:156-62.
30. 30. O'Reilly M, Silver GM, Davis JH, Gamelli RL, Hebert JC. Interleukin-1β improves survival following cecal ligation and puncture. J Surg Res 1992;52:518-22.
31. 31. Zisman DA, Kunkel SL, Strieter RM, Gauldie J, Tsai WC, Bramson J, et al. Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs clearance in murine Escherichia coil peritoneal sepsis. Shock 1997;8:349-56.
32. 32. Zantl N, Uebe A, Neumann B, Wagner H, Siewert JR, Holzmann B, et al. Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect Immun 1998;66:2300-9.
33. 33. Haraguchi S, Day NK, Nelson RP Jr, Emmanuel P, Duplantier JE, Christodoulou CS, et al. Interleukin-12 deficiency associated with recurrent infections. Proc Natl Acad Sci U S A 1998;95:13125-9.
34. 34. Altare F, Lammas D, Revy P, Jouanguy E, Döffinger R, Lamhamedi S, et al. Inherited interleukin 12 deficiency in a child with bacille calmette-Guérin and Salmonella enteritidis disseminated infection. J Clin Invest 1998;102:2035-40.
35. 35. Hensler T, Heidecke CD, Hecker H, Heeg K, Bartels H, Zantl N, et al. Increased susceptibility to postoperative sepsis in patients with impaired monocyte IL-12 production. J Immunol 1998;161:2655-9.
36. 36. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor κB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 1998;24:1131-8.
37. 37. Gérard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993;177:547-50.
38. 38. Platzer C, Meisel C, Vogt K, Platzer M, Volk HD. Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugs. Int Immunol 1995;7:517-23.
39. 39. Hensler T, Hecker H, Heeg K, Heidecke CD, Bartels H, Barthlen W, et al. Distinct mechanisms of immunosuppression as a consequence of major surgery. Int Immunol 1997; 65:2283-91.
40. 40. Brune IB, Wilke W, Hensler T, Holzmann B, Siewert JR. Down-regulation of Th1 immune response and altered proand anti-inflammatory T cell cytokine balance following conventional, but not laparoscopic surgery. Am J Surg 1999; 177:55-60.
41. 41. Stephan RN, Saizawa M, Conrad PJ, Dean RE, Geha AS, Chaudry IH. Depressed antigen presentation function and membrane interleukin-1 activity of peritoneal macrophages after laparotomy. Surgery 1987;102:147-54.
42. 42. Kox WJ. Bone RC, Krausch D, Döcke WD, Kox SN, Wauer H, et al. Interferon γ-1b in the treatment of compensatory anti-inflammatory response syndrome: a new approach: proof of principle. Arch Intern Med 1997;24:389-93.
43. 43. Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med 1997;3:678-81.
44. 44. Yoshimoto T, Wang C-R, Yoneto T, Waki S, Sunaga S, Komagata Y, et al. Reduced T helper 1 responses in IL-12 p40 transgenic mice. J Immunol 1998;160:588-94.